antibiotics Review Extended or Continuous Infusion of Carbapenems in Children with Severe Infections: A Systematic Review and Narrative Synthesis Pengxiang Zhou 1,2,†, Yahui Zhang 1,3,†, Zhenhuan Wang 3,4, Yingqiu Ying 1, Yan Xing 5, Xiaomei Tong 5,* and Suodi Zhai 1,2,* 1 Department of Pharmacy, Peking University Third Hospital, Beijing 100191, China;
[email protected] (P.Z.);
[email protected] (Y.Z.);
[email protected] (Y.Y.) 2 Institute for Drug Evaluation, Peking University Health Science Center, Beijing 100191, China 3 Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China;
[email protected] 4 Department of Pharmacy, First Hospital of Tsinghua University, Beijing 100016, China 5 Department of Pediatrics, Peking University Third Hospital, Beijing 100191, China;
[email protected] * Correspondence:
[email protected] (X.T.);
[email protected] (S.Z.); Tel.: +86-(010)-82267671 (X.T.); +86-(010)-82266686 (S.Z.) † These authors contributed equally to this work. Abstract: We systematically reviewed the efficacy and safety of an extended or continuous infusion (EI/CI) versus short-term infusion (STI) of carbapenems in children with severe infections. Databases, including PubMed, Embase, the Cochrane Library, Clinicaltrials.gov, China National Knowledge Infrastructure, WanFang Data, and SinoMed, were systematically searched from their inceptions to Citation: Zhou, P.; Zhang, Y.; Wang, 10 August 2020, for all types of studies (such as randomized controlled trials (RCTs), retrospective Z.; Ying, Y.; Xing, Y.; Tong, X.; Zhai, S. studies, and pharmacokinetic or population pharmacokinetic (PK/PPK) studies) comparing EI/CI Extended or Continuous Infusion of versus STI in children with severe infection.